March 26, 2019 6:13pm

Sector share value followed the IBB (+1.86%) influencing the Advance/Decline (A/D) line (26/17) yet volume remained low

Pre-open indications: 4 Hits and 2 MISS

News: Mesoblast Limited (MESO +$0.23) the Icahn School of Medicine at Mount Sinai and MESO have entered into a Memorandum of Understanding (MOU) to conduct a confirmatory clinical trial using Revascor (MPC-150-IM) for reduction of gastrointestinal (GI) bleeding in end-stage heart failure patients implanted with a left ventricular assist device (LVAD). Ultragenyx Pharmaceutical (RARE +$2.74) Brazil’s National Health Surveillance Agency (ANVISA) has approved Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older.

 

Review the snapshot of the daily ‘workings” of the sector composite of cell and gene therapy companies.


That’s why my “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.

 

Markets and indexes:

  • The Dow closed up +140.90points or +0.55% to 25,657.73
  • The S&P closed up +20.10 points or +0.72% to 2,818.46
  • The NASDAQ was up +53.98 points or +0.71% to 7,691.52

 

Henry’omics:

Sector share value followed the IBB (+1.86%) influencing the Advance/Decline (A/D) line (26/17) while volume remained low.

I am still concerned my thought or bad dreams of lingering uncertainties – the unknowns as news is strikingly absent.

… Which relates back to my thoughts of confidence in share pricing up swings?

 

Question: Are we also prepared for the lies and lack of full truths re transparencies about the status of a company’s standings in relation to its peers in reporting of their quarterly and fiscal year endings and … run-ways?

 

Investors see a yield-curve inversion as a signal that a recession may be on the horizon, so a rise in long-term rates is being viewed as a positive right now. The yield curve inverted amid the release of weak economic data from the U.S. and around the world as well as a downgraded U.S. economic outlook from the Fed <CNBC>.

From the economic side, “Housing starts fell 8.7% in February, widely missing expectations. Building permits declined, but at a slower rate than forecast by economists. Consumer confidence declined in March to 124.1 from 131.4 in February <The Conference Board>.

 

Sector equities posting gains were: BLUE (+$6.59), SAGE (+$4.01), ALNY (+$2.97), RARE (+$2.74) and GBT (+$1.55)

  • After Monday’s: SAGE (+$2.12), GBT (+$1.38), VYGR (+$1.17), RARE (+$1.08) and AXGN (+$1.01)

Crashing on Monday was: QURE (-$2.07), RENE.L (-$2.00), BLFS (-$0.87), RGNX (-$0.39) and VCEL (-$0.35)

  • After Monday’s: RENE.L (-$2.00), QURE (-$1.4), CRSP (-$1.40), BLFS (-$0.75) and BOLD (-$0.68)

 

Pre-open post, “futures are climbing; sector equities eked out a small gain on Monday; Tuesday, we should see through the forest and a path to the upside. As I stated, “WHAT is the sector about … REPAIR and REPLACE which will also be about their share pricing!”

 

The advance/decline line scenario of 45 covered companies:  

  • The open was positive with the A/DL to 33/10, 2 flat and 1 acquired (AST);
  • The mid-day was positive with an A/DL of 26/16 and 2 flats and 1 acquired;
  • The close was positive with an A/DL of 26/17 and 2 flats and 1 acquired;

 

Pre-open indications 4 HIT and 2 MISS

  • BioLife Solutions (BLFS) closed down -$0.87 – miss;
  • bluebird bio (BLUE) closed up +$6.59 – hit;
  • uniQure NV (QURE) closed down -$2.07 – miss;
  • CRISPER Therapeutics (CRSP) closed up +$0.64 – hit;
  • Editas medicine (EDIT) closed up +$0.39 – hit;
  • Intellia Therapeutics (NTLA) closed up +$0.50 – hit;

 

Tonight’s percentage (%) indicators: 

  • Range of the 26 upside was +0.16% (OSIR) to +6.21% (XON) while the 17 downside ranged from -0.23% (AGTC) to -11.22% (CUR -$0.057).

Volume stat: 

  • 3 out of the 26 upside had higher (than the 3 month average) volume
  • 4 out of the 17 downside experienced greater volume (than the 3 month average)

2 flats – BCLI and BSTG with 1 acquired: 1 (AST)

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Tuesday was up +1.86%;
  • Monday was up +0.14%;
  • Friday was down -3.39%;
  • Thursday was down -1.07%;
  • Wednesday was down -0.59%;
  • Last Tuesday was down -0.06%;

 

March sessions:

Tuesday closed POSITIVE with 17 decliners, 26 advancers, 2 flats and 1 acquired;

Monday (3/25) closed POSITIVE with 21 decliners, 23 advancers, 0 flats and 1 acquired;

Friday closed NEGATIVE with 40 decliners, 2 advancers, 2 flats and 1 acquired;

Thursday closed POSITIVE with 12 decliners, 31 advancers, 1 flat and 1 acquired;

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.